UY26218A1 - Combinacion de inhibidores de mtp e inhibidores de hmg- coa reductasa y su uso en medicamentos. ley 17.164.- - Google Patents

Combinacion de inhibidores de mtp e inhibidores de hmg- coa reductasa y su uso en medicamentos. ley 17.164.-

Info

Publication number
UY26218A1
UY26218A1 UY26218A UY26218A UY26218A1 UY 26218 A1 UY26218 A1 UY 26218A1 UY 26218 A UY26218 A UY 26218A UY 26218 A UY26218 A UY 26218A UY 26218 A1 UY26218 A1 UY 26218A1
Authority
UY
Uruguay
Prior art keywords
combination
inhibitors
hmg
coa reductase
medicines
Prior art date
Application number
UY26218A
Other languages
English (en)
Inventor
Rudi Grutzmann
Ulrich Muller
Hilmar Bischoff
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of UY26218A1 publication Critical patent/UY26218A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere al uso de una combinación de al menos un inhibidor de MTP seleccionado ( componente A ) y un inhibidor de HMg - Coa reductasa ( componente B ) para la lucha contra enfermedades del sistema cardiocirculatorio, a medicamentos que contienen esta combinación y a su obtención.
UY26218A 1999-06-25 2000-06-23 Combinacion de inhibidores de mtp e inhibidores de hmg- coa reductasa y su uso en medicamentos. ley 17.164.- UY26218A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19929065A DE19929065A1 (de) 1999-06-25 1999-06-25 Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln

Publications (1)

Publication Number Publication Date
UY26218A1 true UY26218A1 (es) 2001-01-31

Family

ID=7912459

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26218A UY26218A1 (es) 1999-06-25 2000-06-23 Combinacion de inhibidores de mtp e inhibidores de hmg- coa reductasa y su uso en medicamentos. ley 17.164.-

Country Status (12)

Country Link
EP (1) EP1196194A2 (es)
JP (1) JP2003503342A (es)
AR (1) AR028996A1 (es)
AU (1) AU5680900A (es)
CA (1) CA2376881A1 (es)
DE (1) DE19929065A1 (es)
DO (1) DOP2000000022A (es)
GT (1) GT200000099A (es)
PE (1) PE20010302A1 (es)
SV (1) SV2004000109A (es)
UY (1) UY26218A1 (es)
WO (1) WO2001000183A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
RU2293721C2 (ru) * 2002-02-28 2007-02-20 Джапан Тобакко Инк. Сложноэфирные соединения и их применение в медицине
WO2005021486A1 (ja) * 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109053927A (zh) * 2018-08-08 2018-12-21 中山大学 一种含维生素b12基团的两亲性海藻酸钠衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19546919A1 (de) * 1995-12-15 1997-06-19 Bayer Ag N-Heterocyclisch substituierte Phenylessigsäure-Derivate
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19615265A1 (de) * 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
US6121283A (en) * 1996-11-27 2000-09-19 Pfizer Inc Apo B-secretion/MTP inhibitory amides
WO1998050028A1 (en) * 1997-05-01 1998-11-12 Bristol-Myers Squibb Company Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
AU5680900A (en) 2001-01-31
GT200000099A (es) 2001-12-13
WO2001000183A3 (de) 2001-05-10
EP1196194A2 (de) 2002-04-17
DOP2000000022A (es) 2008-08-15
SV2004000109A (es) 2004-05-07
JP2003503342A (ja) 2003-01-28
PE20010302A1 (es) 2001-04-12
AR028996A1 (es) 2003-06-04
DE19929065A1 (de) 2000-12-28
CA2376881A1 (en) 2001-01-04
WO2001000183A2 (de) 2001-01-04

Similar Documents

Publication Publication Date Title
DOP2000000022A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos.
DOP2019000185A (es) Una formulación sólida de dosificación farmacéutica
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
PA8523901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
BR0317715A (pt) Composições e processos de uso de collajolie
PA8513601A1 (es) Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
UY26092A1 (es) Uso de inhibidores de cyp2d6 en terapias de combinacion
ES2188177T3 (es) Composicion para la prevencion y/o el tratamiento de la osteoporosis y las alteraciones debidas al sindrome menopausico, que comprende propionil-l-carnitina y genisteina.
BRPI0507654A (pt) composição farmacêutica compreendendo um derivado de benzodiazepina e um inibidor da proteìna de fusão de rsv
PA8577901A1 (es) Formulacion farmaceutica
WO2007053641A3 (en) A-type procyanidins and inflammation
TW200510002A (en) Solid pharmaceutical preparation
AR052104A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
PT991654E (pt) Novos derivados de 2-(iminometil)amino-fenilo sua preparacao sua aplicacao como medicamentos e composicoes farmaceuticas que os contem
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
HUP0401854A2 (hu) COX-2 inhibitorokat és aszpirint tartalmazó kombinációk
DK0991424T3 (da) Farmaceutiske præparater omfattende en inhibitor for aldosereduktase og en inhibitor for ACE
UY27753A1 (es) Formulación farmacéutica que comprende melatonina.
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
AR021249A1 (es) COMPOSICIoN DE CONFITURA BLANDA NO PEGAJOSA.
ATE418613T1 (de) Antimikrobielle zusammensetzungen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110721